Neoral-Sandimmun (Ciclosporin)

Ciclosporin, the active ingredient in Neoral‑Sandimmun, is a calcineurin inhibitor presented as an oral formulation for systemic use. It is employed to prevent organ transplant rejection and to manage autoimmune disorders such as psoriasis and rheumatoid arthritis in adult patients.

GNH USA supplies Neoral‑Sandimmun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability.

Neoral‑Sandimmun (ciclosporin) acts as a calcineurin inhibitor to modulate immune responses in several clinical settings.

Organ transplant rejection prevention: reduces the risk of acute and chronic rejection by suppressing T‑cell activation. Psoriasis: improves skin lesions by decreasing inflammatory cytokine production. Rheumatoid arthritis: alleviates joint inflammation and damage through immune modulation.

Ciclosporin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Tremor: fine shaking of the hands. - Hypertension: elevated blood pressure. - Hyperlipidemia: increased cholesterol or triglycerides. - Gum hyperplasia: overgrowth of gingival tissue.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function. - Serious infections: opportunistic bacterial, viral or fungal infections. - Malignancy: increased risk of lymphomas and skin cancers. - Severe allergic reactions: rash, angioedema, anaphylaxis.

Before initiating therapy with Neoral‑Sandimmun, clinicians should consider several precautionary measures to ensure patient safety.

Renal monitoring: assess serum creatinine and glomerular filtration rate regularly. Blood pressure control: monitor and manage hypertension throughout treatment. Lipid profile: check cholesterol and triglyceride levels periodically. Hepatic function: evaluate liver enzymes before and during therapy. Infection risk: avoid use in patients with active uncontrolled infections. Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Ciclosporin is metabolized by CYP3A4 and P‑glycoprotein, leading to several clinically important drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): markedly increase ciclosporin concentrations. - Azole antifungals (e.g., fluconazole): raise blood levels and risk of toxicity. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): elevate drug exposure. - Grapefruit juice: can significantly boost plasma levels. - Certain antivirals (e.g., saquinavir): may cause dangerous accumulation.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., diltiazem, verapamil): may increase ciclosporin levels modestly. - Statins (e.g., simvastatin, atorvastatin): risk of myopathy; dose adjustment may be needed. - NSAIDs: can exacerbate renal impairment. - Rifampin: may reduce ciclosporin concentrations, requiring dose increase. - Diuretics: monitor electrolytes and renal function.